GlySure Appoints William Moffitt as Executive Chairman
MedTech veteran to support GlySure's preparation for commercialization of its
continuous blood glucose monitoring technology
OXFORD, England, June 26, 2013
OXFORD, England, June 26, 2013 /PRNewswire/ --
GlySure Limited, developer of in-hospital continuous blood glucose monitoring
(CBGM) systems, today announced the appointment of William Moffitt as
Moffitt has more than 35 years of experience in the medical diagnostics and
device industry. He takes on the Executive Chairman role at a crucial phase of
GlySure's ongoing development as it commences CE mark trials of its CBGM
Moffitt has an impressive track record of leading corporations of all market
capitalizations in the development and commercialization of cutting-edge
technologies that revolutionize the healthcare industry. He is the past
President and CEO of two of the most technologically disruptive companies in
the MedTech space: Nanosphere, Inc. and i-STAT Corp.
Under Moffitt's leadership Nanosphere transformed itself from a development
stage company to a publicly listed, rapidly growing company with a global
commercial business base. During his tenure at i-STAT, Moffitt led the company
from its early research stage to commercialization with revenue of nearly $100
million and through its initial public offering to acquisition by Abbott
Laboratories in 2003.
"This is a time of tremendous momentum at GlySure as we close our successful
cardiac surgery ICU trial and pursue regulatory approval of our CBGM system,"
said GlySure CEO Chris Jones. "Bill's prolific experience in guiding
transformative medical diagnostics and device companies through to
commercialization is invaluable at this time and for the future of our
Prior to i-STAT Moffitt held executive positions at Baxter Healthcare
Corporation and American Hospital Supply Corporation, which Baxter acquired.
He holds a B.S. from Duke University.
GlySure has developed a continuous intravascular glucose monitoring system
using a proprietary optical fluorescence sensor to meet the $2B+ worldwide
demand for implementation of Tight Glycemic Control (TGC) in the hospital
Intensive Care Unit (ICU). The company has demonstrated through ICU testing
highly accurate sensors which can provide continuous glucose readings
throughout the length of a patient's stay in the ICU. GlySure was founded in
2006, it is based in Abingdon, Oxfordshire, England and it has 30 employees.
The company's products are not approved for use in the U.S. or Europe.
Company Contact: Chris Jones, CEO, GlySure. Tel: +44-(0)1235-462-870.
Media Contact: Kara Della Vecchia, KDV Communications, Inc. Tel:
SOURCE GlySure Limited
Press spacebar to pause and continue. Press esc to stop.